- CV: Si todo va bien la preliminary opinion será el [[2025/01/30]]. In kenya still looking for a local agent. Submissions in latam and india after EMA.
- AB: We're in a good place for PQ. Its not on liconsas side to make the offer. WHO makes out a call for expresions of interest. They have never put out a call for a FDC. We're in the process of supporting WHO to draft that call for a FDC. In early 2025 allow them to Liconsa to react to that: we have a product that can go for your consideration. That would start the formal PQ process. Maybe 6 months, maybe a bit longer. If things go as planned. We anticipate those pieces in early 2025 to follow closely on the tails of the EMA decission. That would fall nicely into place in 2025. They may say that they want to see or weight the extra effectiveness and expanded safety data.
- AB: the call is only for STH. its for an indication and a specific medicine. The level of precision is very narrowly defined.
- AK: They may request additional data. We have started to revise a new version of the systematic review of high dose ivm during the pandemic. Registered in PROSPERO. When any news brought here. That would
- AK: They may request additional data. We have started to revise a new version of the systematic review of high dose ivm during the pandemic. Registered in PROSPERO. When any news brought here. That would be useful
- AB: We've missed the EoI deadline. I didn't know until recently that ALB and IVM arae in the EML, and ALB does specific mention of combination with IVM.
borja
1 month ago